A popular combo of a long-acting GHRH analog and a selective ghrelin-mimetic GH secretagogue, used to stimulate the body's own GH release; limited human efficacy data.
Research use only — neither is an approved medicine with FDA, EMA or MHRA for any indication. Both are growth-hormone secretagogues on the WADA prohibited list and banned in sport. Sold via compounding and gray-market channels.
Also known as: CJC-1295 (with or without DAC), modified GRF(1-29); Ipamorelin (NNC 26-0161)
Complementary pathways: CJC-1295 binds pituitary GHRH receptors (cAMP) with a long half-life that raises GH-pulse amplitude; Ipamorelin binds the GHS-R1a ghrelin receptor (calcium-dependent) adding pulse strength with minimal cortisol/prolactin. Together they produce synergistic GH release.
CJC-1295 is a long-acting GHRH analog; ipamorelin is a selective ghrelin-receptor secretagogue. They are combined because the two pathways stimulate pituitary GH release complementarily. Early pharmacology studies show CJC-1295 durably raises GH and IGF-1, and ipamorelin reliably triggers GH pulses with little cortisol or prolactin effect. But there are essentially no large controlled clinical-outcome trials of the combination for fat loss, muscle gain, recovery or anti-aging — the marketed benefits rest on mechanism and small early studies, not efficacy endpoints. Chronically elevating GH/IGF-1 carries theoretical risks that are poorly studied here.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Injection-site reactions, flushing, headache, water retention and transient hunger (the ghrelin-mimetic effect). Raising GH/IGF-1 can cause insulin resistance, joint pain and oedema. Long-term safety of sustained secretagogue-driven GH elevation in healthy people is not established, and gray-market purity is a real concern.
Almost always discussed as a pair — a GHRH analog plus a ghrelin mimetic for synergistic GH release. Grouped with tesamorelin (another GHRH analog) and sometimes BPC-157 in recovery marketing.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Versus tesamorelin — an approved GHRH analog with phase 3 data — this combo lacks controlled outcome trials and regulatory approval, though it works through a similar upstream mechanism plus an added ghrelin arm.
No. Neither peptide is approved for these uses; they are unlicensed compounds sold through compounding and gray-market routes.
Not from good trials. The compounds do raise GH and IGF-1, but rigorous outcome studies showing meaningful body-composition or recovery benefits are lacking.
No. Both are on the WADA banned list as GH secretagogues, individually and combined.
No reviews yet. If you've used CJC-1295 / Ipamorelin, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.